


Appl. No.: 10/528,444
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

CLAIMS

Claim 1 (currently amended): A triptolide derivative of formula I




I

wherein R1 is [[H,]] phosphate ($-\text{P}(\text{O})(\text{Ox}_1)(\text{Ox}_2)$), or phosphite ($-\text{P}(\text{H})(\text{Ox}_1)(\text{Ox}_2)$), and X₁ and X₂ are Na, K, or NH₄.

Claim 2 (original): A method for preparation of the compound according to claim 1, comprising the step of reacting the first lead compound triptolide with POCl₃, PCl₃ or other phosphonate halide, phosphate, phosphite halide, phosphite.

Claim 3 (currently amended): A triptolide derivative of formula II



II

BEST AVAILABLE COPY

Appl. No.: 10/528,444
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

Claim 7 (currently amended): The compound of claim 5 wherein said compound is used ~~Use of the compounds according to any one of claims 1, 3, and 5~~ in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.


Claim 8 (original): The use according to claim 7, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

Claim 9 (original): The use according to Claim 8, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

Claim 10 (original): The use according to claim 9, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 11 (original): The use according to claim 7, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

Claim 12 (new): A triptolide derivative of formula IIIb



IIIb

wherein R₂ is H, SCN, Cl or Br.

Appl. No.: 10/528,444
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

Claim 13 (new): A method for preparation of the compound according to claim 12, comprising the step of reacting the second lead compound 12- β -thiocyano-13- α -hydroxy triptolide with POCl_3 or other phosphonate halide, phosphate, phosphite and the like, or the step of reacting the first lead compound triptolide with POCl_3 or other phosphonate halide, phosphite halide and the like.

Claim 14 (new): The compound of Claim 12 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

Claim 15 (new): The use according to claim 14, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

Claim 16 (new): The use according to claim 15, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

Claim 17 (new): The use according to claim 16, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 18 (new): The use according to claim 14, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

Claim 19 (new): The compound of Claim 3 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

Claim 20 (new): The use according to claim 19, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

Appl. No.: 10/528,444
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

Claim 21 (new): The use according to claim 20, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

Claim 22 (new): The use according to claim 21, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 23 (new): The use according to claim 19, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

Claim 24 (new): The compound of Claim 1 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

Claim 25 (new): The use according to claim 24, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

Claim 26 (new): The use according to claim 25, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

Claim 27 (new): The use according to claim 26, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 28 (new): The use according to claim 24, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

Claim 29 (new): The compound according to Claim 3 wherein R_1 is one of a phosphate ($-\text{P}(\text{O})(\text{O}X_1)(\text{O}X_2)-$) or a phosphite ($-\text{P}(\text{O})(\text{O}X_1)(\text{H})-$) and wherein X_1 and X_2 are Na or K or NH_4 and R_2 is H or SCN or Cl or Br.

Appl. No.: 10/528,444
Amendment Dated October 18, 2005

Attorney Docket No. 58260-011600

Claim 30 (new): The compound of Claim 29 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent.

Claim 31 (new): The use according to claim 30, wherein said immunosuppressive agent or anti-inflammatory agent is used in the treatment of diseases associated with growth of lymphocytes T and B cells; production of cytokines such as IL-1, IL-2, IL-6, and iNOS; and production of Cox-2.

Claim 32 (new): The use according to claim 31, wherein said diseases are autoimmune deficiency diseases and inflammatory diseases.

Claim 33 (new): The use according to claim 32, wherein said diseases are selected from the group consisted of rheumatoid arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 34 (new): The use according to claim 30, wherein said immunosuppressive agent or anti-inflammatory agent is used in the prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation.

Claim 35 (new): A method for preparation of the compound according to claim 5, comprising the step of reacting the first lead compound triptolide with POCl_3 , or other phosphonate halide, phosphate halide and the like.

Claim 36 (new): A method for preparation of the compound according to claim 3, comprising the step of phosphoric esterifying the second lead compound 12- β -thiocyano-13- α -hydroxy triptolide with POCl_3 , PCl_3 , phosphonate halide, phosphate, phosphite halide, or phosphate to obtain the compound of formula II.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.